News - Roche

Filter

Current filters:

Roche

Popular Filters

51 to 75 of 372 results

US and European retinal specialists view AMD treatments

US and European retinal specialists view AMD treatments

14-03-2014

Surveyed US and European retinal specialists ascribe a moderate to high unmet need for wet age-related…

BayerEuropeEyleaFovistaLucentisMarkets & MarketingNovartisOphthalmicsOphthotechPharmaceuticalRegeneronRocheUSA

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

Roche and Novartis fined for cartelizing sales of eye drugs Avastin and Lucentis in Italy

06-03-2014

Swiss pharma majors Roche and Novartis colluded to exclude the cheaper cancer drug Avastin (bevacizumab),…

AvastinEuropeFinancialItalyLegalLucentisNovartisOphthalmicsPharmaceuticalRoche

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

AAAAI 2014: Roche’s lebrikizumab shows reduction of asthma attack rates

05-03-2014

Swiss drug major Roche has presented new data from the LUTE / VERSE Phase IIb studies for the investigational…

ImmunologicalslebrikizumabPharmaceuticalResearchRespiratory and PulmonaryRocheUSA

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

UK’s NICE does U-turn on Pfizer’s Inlyta for advanced kidney cancer

04-03-2014

UK drug watchdog the National Institute for Health and Care Excellence (NICE) this morning published…

InlytaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheUK

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

03-03-2014

An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…

BiotechnologyGenentechonartuzumabOncologyResearchRoche

Roche collaborates with Discuva to combat life-threatening infections

28-02-2014

Swiss pharma major Roche and privately-held UK biotech firm Discuva have entered into a worldwide collaboration…

Antibiotics and Infectious diseasesDiscuvaLicensingPharmaceuticalResearchRoche

Which place for orphan drugs in the strategy of pharma companies and payers?

27-02-2014

As the 7th Rare Disease Day will be held on February 28, ALCIMED, an innovation and new business consulting…

Markets & MarketingNovartisPharmaceuticalPricingRare diseasesResearchRocheSanofi

Funding restrictions for rituximab and eltrombopag widened in New Zealand

Funding restrictions for rituximab and eltrombopag widened in New Zealand

20-02-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of proposals to widen…

Asia-PacificeltrombopagFinancialGlaxoSmithKlineHealthcareImmunologicalsNew ZealandPharmaceuticalrituximabRoche

Avastin seen to prolong life for women with advanced cervical cancer

Avastin seen to prolong life for women with advanced cervical cancer

20-02-2014

Swiss drug major Roche’s blockbuster cancer drug Avastin (bevacizumab) can extend the lives of women…

AvastinOncologyPharmaceuticalResearchRoche

Roche’s breast cancer drug Kadcyla debuts in UK

Roche’s breast cancer drug Kadcyla debuts in UK

13-02-2014

Swiss drug major Roche’s Kadcyla (ado-trastuzumab emtansine or T-DM1) is now available for UK patients…

KadcylaMarkets & MarketingNorthern EuropeOncologyPharmaceuticalRocheUK

UK’s NICE consults on updating guidance for Tarceva and Iressa

UK’s NICE consults on updating guidance for Tarceva and Iressa

04-02-2014

The UK’s National Institute for Health and Care Excellence (NICE) said this morning that it is reviewing…

AstraZenecadocetaxelIressaOncologyPharmaceuticalRegulationRocheTarcevaUK

PDL BioPharma settles litigation with Genentech and Roche

03-02-2014

US drugmaker PDL BioPharma has entered into an agreement with Genentech and its parent, Swiss drug major…

BiotechnologyFinancialGenentechLegalOncologyOphthalmicsPDL BioPharmaRoche

Mylan debuts Hertraz, first Herceptin biosimilar, in India

Mylan debuts Hertraz, first Herceptin biosimilar, in India

03-02-2014

US generics major Mylan has launched the world's first trastuzumab biosimilar in India. The product,…

Asia-PacificBioconBiosimilarsGenericsHerceptinHertrazIndiaMarkets & MarketingMylan LaboratoriesOncologyRoche

Roche sees strong 2013 sales growth, but still disappoints

Roche sees strong 2013 sales growth, but still disappoints

30-01-2014

Swiss drug major Roche posted full-year 2013 financial results this morning, showing that group sales…

FinancialRoche

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

UK’s NICE gives green light to Roche’s MabThera for GPA and MPA

24-01-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) today approved the use…

EuropeImmunologicalsMabTheraPharmaceuticalPricingRegulationRocheUK

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

Prothena to get $30 million upfront from Roche triggered by regulatory milestone

23-01-2014

Clinical-stage biotech firm Prothena said today that it will receive the $30 million upfront payment…

BiotechnologyFinancialLicensingNeurologicalProthenaPRX002Roche

Disappointing results for Roche in Phase III schizophrenia studies

Disappointing results for Roche in Phase III schizophrenia studies

21-01-2014

Swiss drug major Roche (ROG: SIX) has revealed disappointing results from two Phase III studies of its…

bitopertinNeurologicalNorthern EuropePharmaceuticalResearchRoche

MAb market for gastric and esophageal cancer expected to double by 2019

MAb market for gastric and esophageal cancer expected to double by 2019

18-01-2014

Due to favorable market conditions in terms of US pricing structures and the anticipated approval of…

BiotechnologyHerceptinMarkets & MarketingOncologyRoche

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

Breakthrough year for unmet diseases, as FDA backs 37 designations in 2013

17-01-2014

Since the US Food and Drug Administration’s breakthrough therapy designation (BTD) was put into effect…

GazyvaGilead SciencesImbruvicaJohnson & JohnsonPharmaceuticalRegulationRocheSovaldiUSA

Celltrion’s trastuzumab biosimilar, Herzuma, approved in South Korea

16-01-2014

South Korean biopharmaceutical firm Celltrion has received approval for its cancer treatment biosimilar…

Asia-PacificBiosimilarsCellTrionGenericsHerceptinHerzumaOncologyRegulationRoche

51 to 75 of 372 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top